Trial · NCT04392154
Participant flow32
How many started, completed or left each group, period by period.
1 to 20 of 32
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Primary Treatment Period (100 Weeks) | STARTED | Primary Treatment Period: Lebrikizumab Q4W | 141 | |
| Primary Treatment Period (100 Weeks) | STARTED | Primary Treatment Period: Lebrikizumab Q2W | 1,012 | |
| Primary Treatment Period (100 Weeks) | STARTED | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | |
| Primary Treatment Period (100 Weeks) | STARTED | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | |
| Primary Treatment Period (100 Weeks) | Received at Least 1 Dose of Study Drug | Primary Treatment Period: Lebrikizumab Q4W | 141 | |
| Primary Treatment Period (100 Weeks) | Received at Least 1 Dose of Study Drug | Primary Treatment Period: Lebrikizumab Q2W | 1,012 | |
| Primary Treatment Period (100 Weeks) | Received at Least 1 Dose of Study Drug | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | |
| Primary Treatment Period (100 Weeks) | Received at Least 1 Dose of Study Drug | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | |
| Primary Treatment Period (100 Weeks) | COMPLETED | Primary Treatment Period: Lebrikizumab Q4W | 103 | |
| Primary Treatment Period (100 Weeks) | COMPLETED | Primary Treatment Period: Lebrikizumab Q2W | 675 | |
| Primary Treatment Period (100 Weeks) | COMPLETED | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | |
| Primary Treatment Period (100 Weeks) | COMPLETED | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | |
| Primary Treatment Period (100 Weeks) | NOT COMPLETED | Primary Treatment Period: Lebrikizumab Q4W | 38 | |
| Primary Treatment Period (100 Weeks) | NOT COMPLETED | Primary Treatment Period: Lebrikizumab Q2W | 337 | |
| Primary Treatment Period (100 Weeks) | NOT COMPLETED | Open-Label Extension Addendum: Lebrikizumab Q4W | 0 | |
| Primary Treatment Period (100 Weeks) | NOT COMPLETED | Open-Label Extension Addendum: Lebrikizumab Q8W | 0 | |
| Open-Label Extension Addendum (32 Weeks) | STARTED | Primary Treatment Period: Lebrikizumab Q4W | 0 | |
| Open-Label Extension Addendum (32 Weeks) | STARTED | Primary Treatment Period: Lebrikizumab Q2W | 0 | |
| Open-Label Extension Addendum (32 Weeks) | STARTED | Open-Label Extension Addendum: Lebrikizumab Q4W | 52 | |
| Open-Label Extension Addendum (32 Weeks) | STARTED | Open-Label Extension Addendum: Lebrikizumab Q8W | 51 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04392154/flow